#glp-1-receptor-agonists

[ follow ]
#eli-lilly
Wearables
fromNew York Post
6 months ago

Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic

Eli Lilly's orforglipron shows significant weight loss for Type 2 diabetes patients, potentially rivaling injectable medications.
Lilly's shares surged 15% following promising clinical trial results for orforglipron.
Wearables
fromNew York Post
6 months ago

Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic

Eli Lilly's orforglipron shows significant weight loss for Type 2 diabetes patients, potentially rivaling injectable medications.
Lilly's shares surged 15% following promising clinical trial results for orforglipron.
fromwww.scientificamerican.com
3 hours ago

The New Weight-Loss Drugs Don't Work for Everyone. Genetics May Explain Why

People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and the related health benefits, but many doctors at weight-loss clinics are noticing a puzzling response in certain individuals. Andres J. Acosta, a gastroenterologist at the Mayo Clinic, says some of his patients have expressed frustration and disappointment as they watch friends or colleagues drop significant weight while taking the drugs but lose little or no weight themselveseven when they adhere to the medication's instructions perfectly.
Medicine
Medicine
fromScienceDaily
1 week ago

Surgery beats Ozempic for long-term health, Cleveland Clinic finds

Weight-loss (bariatric) surgery reduces mortality and major cardiovascular, renal, and eye complications more than GLP-1 receptor agonists for people with obesity and type 2 diabetes.
#weight-loss
Cancer
fromwww.theguardian.com
5 months ago

Weight-loss jabs could halve risk of obesity-related cancers, study finds

Weight-loss injections significantly reduce the risk of obesity-related cancers, suggesting a new approach to preventive medicine.
fromenglish.elpais.com
1 month ago

Why weight loss drugs don't work the same for everyone: The frontier of emotional eating

A group of scientists monitored 92 people with diabetes in Japan during their first year of treatment with weight-loss drugs and discovered that the patient's psychology can affect the success of these therapies. People who overate at the sight or smell of tasty food were more likely to respond well to the drugs over the long term, while those who overate for emotional reasons were less likely to do so.
Medicine
#obesity
fromwww.theguardian.com
4 months ago

Weight loss drugs linked to higher risk of eye damage in diabetic patients

The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration.
Alternative medicine
Alternative medicine
fromenglish.elpais.com
6 months ago

The Ozempic universe expands: These drugs also treat fatty liver disease

Ozempic drugs show promise in treating fatty liver disease, halting or reversing its progression, and may provide broader therapeutic effects beyond weight loss.
[ Load more ]